Will Smith’s Son, Jaden, Is Also Into Psychedelics
But the 23-year-old actor and musician doesn’t specify which psychedelics he uses to explore “mystical states of consciousness.”
Psychedelic Spotlight News
-
-
World Boxing Association Partners with Psychedelics Company for TBI and PTSD Research
“We believe in the promise of the resurgence of psychedelic medicine and are proud to be collaborating with Lobe Sciences as we work together to improve the lives and health of members of the WBA family,” says WBA president Gilberto Jesús Mendoza.
-
Will Smith Comes Out of the Psychedelic Closet
And it sounds like we’ll hear more about his psychedelic experiences on ayahuasca in his upcoming memoir, simply titled “Will.”
-
Psychedelic Business Spotlight: October 1, 2021
This week in psychedelic business news: more evidence supporting ketamine for depression; a new use for MDMA; Lobe Sciences makes a leap in treating PTSD; Delix raises big bucks; and BetterLife Pharma patents solution for cluster headaches.
-
Majority of Oregon Adults Interested in Psilocybin Want to Try Microdosing
On the flip side, 37% of Oregon adults surveyed said they did not know what psilocybin was.
-
World’s Richest Person Elon Musk: ‘People Should Be Open to Psychedelics’
The Tesla and SpaceX founder, estimated to be worth nearly $200 billion, has previously hinted at using DMT.
-
Why NeonMind Is Betting on Psilocybin to Curb the Global Obesity Epidemic
The psychedelic bioscience company’s top advisor tells Psychedelic Spotlight that psilocybin “affects at least the 5h2C receptor, which is dedicated towards appetite and appetite suppression.”
-
Wonderland Miami Brings Together Psychedelic Industry Leaders and Celebrity Advocates
Organizers of the largest psychedelic business event ever promise it’s not just a conference, but an experience.
-
Mind Cure Health Targeting Hypoactive Sexual Desire Disorder with MDMA
“Women’s desire issues have not been adequately addressed to date, and we believe this treatment incorporating MDMA and psychotherapy has real promise,” says CEO Kelsey Ramsden
-
MindMed Releases Data on TWO Clinical Trials: A Closer Look Into MMED’s Psilocybin and LSD studies
MindMed Releases Data on TWO Clinical Trials: A Closer Look Into MMED’s Psilocybin and LSD studies.
Mind Medicine (MindMed), (NASDAQ: MNMD, NEO: MMED, DE: MMQ), announced that Dr. Matthias Liechti presented data from several ongoing studies at the INSIGHT Conference in Berlin, Germany, conducted as part of MindMed’s ongoing collaboration with the UHB Liechti Lab.
STUDIES:
https://clinicaltrials.gov/ct2/show/NCT03912974?term=psilocybin+escitalopram&draw=2&rank=2https://clinicaltrials.gov/ct2/show/NCT03604744?term=LSD+PSilocybin&draw=2&rank=1
https://mindmed.co/news/press-release/mindmed-and-liechti-lab-provide-results-from-their-psilocybin-rd-collaboration/?fbclid=IwAR2_2fUvNf-VTF36Sv6Oz-XB8PTjscqjMWMFF5CKBvKQU2yLMOI_ZP4aq18
Enjoy the episode!Follow us on social media! 🙌
Instagram: @thepsychedelicinvestor
Facebook: @thepsychedelicinvestorWant to collaborate? Send us an email at:
thepsychedelicinvestor@gmail.comMusic from:
www.bensound.comVideo editing: @themyaholy
Check out our Benziga discounts
https://benzinga.grsm.io/jameshallifax1834
https://benzinga.grsm.io/thepsychedelicinvestorDISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.
#mindmed #mmed #mnmdstock
